BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36806982)

  • 21. Unexpected finding of a rare pathogenic germline BRCA1 variant in an intrahepatic cholangiocarcinoma using the Oncomine Focus DNA assay: clinical and diagnostic implications.
    De Bonis M; Mannavola F; Salvatore L; De Paolis E; Nero C; Giacò L; Tortora G; Giuliante F; Urbani A; Scambia G; Normanno N; Minucci A
    Mol Biol Rep; 2023 Aug; 50(8):7113-7120. PubMed ID: 37340184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Surgical Resection after Gemcitabine plus Cisplatin Chemotherapy for Intrahepatic Cholangiocarcinoma with Multiple Lymph Node Metastases - Report of a Case].
    Otani T; Sakata J; Kameyama H; Otani A; Hirose Y; Tamura H; Morimoto Y; Miura K; Yoshino K; Kido T; Kobayashi T; Endo K; Wakai T
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1764-1766. PubMed ID: 28133124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
    J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metastatic colorectal cancer as the primary phenotype in a hereditary breast and ovarian cancer patient with Germline BRCA1 mutation: a case report.
    Liu Y; Zhu J; Wei X; Yang D; Li S; Qian X; Li L
    J Ovarian Res; 2022 Dec; 15(1):127. PubMed ID: 36463302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors.
    Ryu JM; Nam SJ; Kim SW; Lee JE; Chae BJ; Lee SK; Yu J
    Jpn J Clin Oncol; 2020 Feb; 50(2):104-113. PubMed ID: 31926487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrahepatic Cholangiocarcinoma with High Microsatellite Instability and Tumor Mutation Burden That Responded Significantly to Pembrolizumab but Perforated within a Short Period.
    Yamazaki S; Kubota K; Shimizu A; Notake T; Umemura K; Kamachi A; Goto T; Tomida H; Yamashita N; Sato M; Kanno H; Soejima Y
    Intern Med; 2024 Apr; 63(8):1105-1112. PubMed ID: 37779076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report.
    Eso Y; Uza N; Yamagishi H; Imada K; Kimura Y; Masui T; Kodama Y; Seno H
    Medicine (Baltimore); 2017 Dec; 96(50):e9217. PubMed ID: 29390348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
    Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
    Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients.
    Deng H; Chen M; Guo X; Heng J; Xu X; Peng L; Jiang H; Li G; Day JX; Li J; Shan D; Li Y; Zhou Y; Liu B; Dai L; Wang X; Wang J
    Mol Genet Genomic Med; 2019 Jun; 7(6):e672. PubMed ID: 30972954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.
    Takahashi M; Chiba N; Shimodaira H; Yoshino Y; Mori T; Sumii M; Nomizu T; Ishioka C
    Breast Cancer; 2017 Mar; 24(2):336-340. PubMed ID: 27271530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy.
    Chen TC; Jan YY; Yeh TS
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S675-81. PubMed ID: 22805857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.
    Zhu AX; Knox JJ
    Oncologist; 2012; 17(12):1504-7. PubMed ID: 23220842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
    Lee K; Yoo C; Kim KP; Park KJ; Chang HM; Kim TW; Lee JL; Lee W; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
    Invest New Drugs; 2018 Feb; 36(1):163-169. PubMed ID: 28782087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
    Shi T; Wang P; Xie C; Yin S; Shi D; Wei C; Tang W; Jiang R; Cheng X; Wei Q; Wang Q; Zang R
    Int J Cancer; 2017 May; 140(9):2051-2059. PubMed ID: 28176296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
    JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A case of intrahepatic cholangiocarcinoma with peritoneal dissemination treated successfully with surgical resection and adjuvant chemotherapy].
    Shiozaki S; Satoh D; Matsukawa H; Yamaguchi K; Takahashi K; Mimura N; Taguchi K; Araki H; Toshima T; Kato T; Miyake S; Miyoshi H; Yoshida K; Choda Y; Tokumoto N; Kanazawa T; Harano M; Ojima Y; Idani H; Okajima M; Ninomiya M
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2089-91. PubMed ID: 25731432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of surgical treatment and poor prognostic factors for patients with intrahepatic cholangiocarcinoma: retrospective analysis of 60 patients.
    Yamashita Y; Taketomi A; Morita K; Fukuhara T; Ueda S; Sanefuji K; Iguchi T; Kayashima H; Sugimachi K; Maehara Y
    Anticancer Res; 2008; 28(4C):2353-9. PubMed ID: 18751418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A case of curatively resected intrahepatic cholangiocarcinoma with hepatic artery and portal vein reconstruction].
    Matsuura Y; Wada H; Tomimaru Y; Tomokuni A; Hama N; Kawamoto K; Kobayashi S; Marubashi S; Eguchi H; Umeshita K; Doki Y; Mori M; Nagano H
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2086-8. PubMed ID: 25731431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.
    Guglielmi A; Ruzzenente A; Campagnaro T; Pachera S; Valdegamberi A; Nicoli P; Cappellani A; Malfermoni G; Iacono C
    World J Surg; 2009 Jun; 33(6):1247-54. PubMed ID: 19294467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.